Share this article and save a life!
The FDA just made its boldest move in 118 years of existence.
They’ve deployed agentic AI systems across the entire agency.
Not chatbots. Not basic automation.
Actual AI agents that can autonomously execute complex regulatory workflows while humans maintain oversight.
🚀 What this means:
Pre-market reviews that took months? Now potentially weeks.
Post-market surveillance catching safety signals? Near real-time.
Inspection reports and administrative backlogs? Dramatically reduced.
The numbers tell the story:
• Over 1,000 AI medical devices awaiting review
• 873 radiology AI algorithms approved in 2025 alone
• Review delays threatening patient access to innovation
• Workforce reductions pressuring the agency
Here’s what’s revolutionary:
These aren’t simple tools. They’re hosted in high-security GovCloud, protected from training on submitted data, and include mandatory human oversight checkpoints.
The FDA launched an internal Agentic AI Challenge to validate use cases across departments.
But here’s the tension:
While the agency races to modernize, they still haven’t published detailed validation standards. Industry groups are pushing for clearer post-market evaluation frameworks.
And the elephant in the room?
The FDA hasn’t approved a single LLM-based medical device yet, even as they deploy LLMs internally.
This paradox reveals something profound about healthcare innovation:
The regulators themselves need AI to keep pace with the AI they’re regulating.
It’s regulatory recursion at its finest.
Think about the implications:
If AI agents can accelerate drug approvals by 50%, how many life-saving treatments reach patients sooner?
If post-market surveillance becomes real-time, how many adverse events get prevented?
If administrative burden drops dramatically, can FDA staff focus on complex safety questions that truly need human judgment?
This isn’t just about efficiency.
It’s about fundamentally reimagining how we balance innovation with safety in an exponential technology era.
The FDA’s move signals something bigger:
Regulatory agencies worldwide will follow. The traditional pace of government oversight is officially obsolete.
We’re entering an era where AI regulates AI, with humans setting the guardrails.
Welcome to the future of healthcare regulation.
♻️ Repost if AI should accelerate life-saving medical innovations
👉 Follow me, Jonathan Govette, for real-time updates on healthcare technology and business news. LinkedIn Profile: https://www.linkedin.com/in/jonathangovette/
Share this article and save a life!
Author:
CEO/Co-Founder @ Oatmeal Health | AI Lung Cancer Screening | Almost Became a Doctor | Engineer | Follow to Share What I’ve Learned Along the Way
I help patients get the care they need earlier, preventing late-stage cancer.
That’s been the throughline across three companies and almost 20 years in healthcare. At ReferralMD, we fixed broken referral networks so patients didn’t fall through the cracks. At Oatmeal Health, it’s lung cancer: building the diagnostic and screening infrastructure so the 85% of cases caught too late get caught early instead.
Today as CEO of Oatmeal Health, I lead a team embedding AI into radiology workflows to turn routine lung CT scans into reimbursable cancer risk assessments. We partner with FQHCs to reach underserved communities, and with health systems and payers to make early detection economically sustainable. Think HeartFlow or Cleerly, but for lungs.
Between companies, I advised at Techstars and Plug and Play, mentoring founders building in digital health. That experience shaped how I think about what separates companies that ship from companies that stall: distribution, reimbursement, and clinical trust, not just technology.
I’m a CancerX alumnus, a 3x healthcare founder, and someone who believes the biggest problems in cancer aren’t scientific. They’re operational.
We’re hiring mission-driven builders at Oatmeal Health. If you want to work on something that matters, reach out.
When I’m not working, I’m traveling, mentoring, and keeping up with one very energetic husky. 🐾
Substack – The Oatmeal Bite:
Millions of patients get less care because of who they are, where they live, or how they look. I’m fighting to change that. CEO @OatmealHealth, a startup built for the underserved. The Oatmeal Bite: intel for clinicians, investors, and advocates.
Jonathan Govette
CEO of Oatmeal Health
Substack:
https://oatmealhealthjonathangovette.substack.com/
